Strides Pharma Science Limited

Strides Pharma Science Limited, established in 1990, is a prominent Indian pharmaceutical company headquartered in Bengaluru, Karnataka. The company specializes in the development and manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. In July 2018, Strides Shasun Limited rebranded itself as Strides Pharma Science Limited to better reflect its global presence and diversified portfolio.

As of March 2026, Strides Pharma Science Limited reported a total export value of $179.3 million USD, with 4,091 shipments across 42 products spanning 20 therapeutic categories. The company's product portfolio is notably concentrated, with the top five products—Rosuvastatin, Vancomycin, Gabapentin, Prednisone, and Ibuprofen—accounting for 45.3% of total exports. Prednisone leads with a 36.0% market share, while Rosuvastatin holds a 4.5% share.

Strides Pharma Science Limited operates a global manufacturing footprint with eight facilities across four continents. In India, the company has multiple plants, including those in Bengaluru, Chennai, and Puducherry, which produce a range of dosage forms such as soft and hard gelatin capsules, tablets, and injectables. Internationally, Strides owns Beltapharm S.R.L. in Italy, enhancing its European presence.

The leadership team at Strides Pharma Science Limited is headed by Managing Director and CEO Badree Komandur, who has been instrumental in steering the company's strategic direction. Vikesh Kumar serves as the Chief Financial Officer, overseeing financial operations and investor relations. Other key executives include P. V. S. Ramaraju, the Chief Operating Officer, and Aditya Arun Kumar, the Executive Director of Business Development.

Strides Pharma Science Limited has established a significant presence in regulated markets, including the United States, Europe, the United Kingdom, Australia, and Japan. The company operates five US FDA-approved facilities, ensuring compliance with stringent regulatory standards. In Europe, Strides owns Beltapharm S.R.L. in Italy, enhancing its market access. The company's commitment to quality and compliance has facilitated its entry into these markets, allowing it to offer a diverse range of pharmaceutical products.

Strides Pharma Science Limited has expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's partnership with the Clinton Foundation has enabled it to supply lower-cost anti-retroviral drugs for the treatment of HIV/AIDS, demonstrating its commitment to global health initiatives. Additionally, Strides is listed as a WHO pre-qualified supplier, allowing it to participate in global procurement programs for essential medicines.

Strides Pharma Science Limited's geographic strategy involves a balanced approach, with a strong presence in both regulated and emerging markets. The company's operations in regulated markets provide stability and adherence to stringent quality standards, while its expansion into emerging markets offers growth opportunities and diversification. This strategic diversification mitigates concentration risk and positions Strides to capitalize on global pharmaceutical demand.

Strides Pharma Science Limited maintains a robust relationship with the US FDA, operating five FDA-approved facilities. The company has a history of successful ANDA (Abbreviated New Drug Application) approvals, reflecting its capability to bring generic drugs to the US market. Additionally, Strides has filed multiple DMFs (Drug Master Files), ensuring transparency and compliance with FDA requirements. The company's facilities have undergone FDA inspections, demonstrating adherence to Good Manufacturing Practices (GMP).

Strides Pharma Science Limited's commitment to quality is evident through its WHO prequalification status, allowing it to supply essential medicines globally. The company's EU GMP certificates further validate its adherence to European manufacturing standards, facilitating market access in the European Union. These certifications underscore Strides' dedication to maintaining high-quality manufacturing processes across its facilities.

In India, Strides Pharma Science Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with national regulatory standards. The company has obtained approvals from various state drug controllers, facilitating the distribution of its products across the country. Additionally, Strides has secured export No Objection Certificates (NOCs), enabling it to export pharmaceutical products to international markets.

As of March 2026, Strides Pharma Science Limited has maintained a clean regulatory record, with no reported Form 483 observations, warning letters, or import alerts from the FDA. The company's commitment to quality and compliance has ensured smooth operations across its manufacturing facilities.

In the pharmaceutical industry, Strides Pharma Science Limited faces competition from major players such as Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, and Cipla Ltd. While Strides holds a leading position in certain therapeutic categories, its competitors have a broader product portfolio and larger market share in various segments. Strides' focus on niche and technically complex formulations differentiates it from competitors, allowing it to cater to specialized market needs.

Strides Pharma Science Limited's key differentiators include its specialization in niche and technically complex pharmaceutical formulations, making it one of the world's largest manufacturers of soft gelatin capsules. The company's global manufacturing footprint, with facilities in multiple countries, and its commitment to quality and compliance, as evidenced by its WHO prequalification and EU GMP certifications, further distinguish it in the competitive landscape.

Strides Pharma Science Limited's current strategic direction focuses on the development and manufacture of generic pharmaceuticals, with an emphasis on niche and complex formulations. The company's expansion into regulated markets, coupled with its presence in emerging markets, positions it for sustained growth. Future outlooks suggest continued investment in research and development to enhance its product portfolio and maintain a competitive edge in the global pharmaceutical industry.

Strides Pharma Science Limited has a strong track record in the pharmaceutical industry, with consistent export volumes and a diverse product portfolio. The company's adherence to international quality standards, as demonstrated by its various certifications, and its reliable supply chain operations, underscore its reliability as a supplier. Strides' focus on niche and complex formulations further enhances its appeal to partners seeking specialized pharmaceutical products.

Importers should verify the following certifications when considering Strides Pharma Science Limited as a supplier:

• FDA Approval: Confirm the company's facilities are FDA-approved by reviewing the FDA's official database.

• WHO-GMP Certification: Verify WHO prequalification status through the WHO's official website.

• EU GMP Certification: Check for EU GMP certificates via the European Medicines Agency (EMA) website.

• ISO Certification: Request copies of ISO certificates directly from Strides Pharma Science Limited or consult the International Organization for Standardization (ISO) database.

When conducting due diligence on Strides Pharma Science Limited, consider the following steps:

• Facility Audits: Schedule visits to manufacturing facilities to assess compliance with quality standards.

• Regulatory Compliance: Review the company's history of regulatory approvals and any past violations.

• Financial Health: Analyze financial statements to evaluate profitability and financial stability.

• Supply Chain Reliability: Assess the consistency and reliability of the company's supply chain operations.

• Product Portfolio: Examine the diversity and quality of the product portfolio to ensure it meets market demands.

Be vigilant for any discrepancies in certifications, unexplained regulatory issues, or financial irregularities that may indicate potential risks.